These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

236 related items for PubMed ID: 10220523

  • 1. A comparison of budesonide and mesalamine for active Crohn's disease.
    Lowry PW, Sandborn WJ.
    Gastroenterology; 1999 May; 116(5):1263. PubMed ID: 10220523
    [No Abstract] [Full Text] [Related]

  • 2. [Drug therapy of Crohn's disease: slowly increase or start aggressively right away?].
    Bischoff A.
    MMW Fortschr Med; 2010 Jan 14; 152(1-2):20. PubMed ID: 20302159
    [No Abstract] [Full Text] [Related]

  • 3. A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group.
    Thomsen OO, Cortot A, Jewell D, Wright JP, Winter T, Veloso FT, Vatn M, Persson T, Pettersson E.
    N Engl J Med; 1998 Aug 06; 339(6):370-4. PubMed ID: 9691103
    [Abstract] [Full Text] [Related]

  • 4. Budesonide versus mesalamine for maintaining remission in patients refusing other immunomodulators for steroid-dependent Crohn's disease.
    Mantzaris GJ, Petraki K, Sfakianakis M, Archavlis E, Christidou A, Chadio-Iordanides H, Triadaphyllou G.
    Clin Gastroenterol Hepatol; 2003 Mar 06; 1(2):122-8. PubMed ID: 15017504
    [Abstract] [Full Text] [Related]

  • 5. [Acute episode].
    Schölmerich J, German Society for Digestive and Metabolic Diseases.
    Z Gastroenterol; 2003 Jan 06; 41(1):27-30. PubMed ID: 12541170
    [No Abstract] [Full Text] [Related]

  • 6. [New research results give hope. Causal therapy of Crohn disease in sight].
    MMW Fortschr Med; 2004 Apr 01; 146(14):42-3. PubMed ID: 15344754
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. [Maintaining a remission].
    Fleig WE, German Society for Digestive and Metabolic Diseases.
    Z Gastroenterol; 2003 Jan 01; 41(1):36-42. PubMed ID: 12541172
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Conventional treatment of Crohn's disease: objectives and outcomes.
    Rutgeerts PJ.
    Inflamm Bowel Dis; 2001 May 01; 7 Suppl 1():S2-8. PubMed ID: 11380039
    [Abstract] [Full Text] [Related]

  • 15. Aminosalicylates for induction of remission or response in Crohn's disease.
    Lim WC, Hanauer S.
    Cochrane Database Syst Rev; 2010 Dec 08; (12):CD008870. PubMed ID: 21154400
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [New therapeutic modalities in Crohn's disease].
    Rachmilewitz D.
    Harefuah; 1999 Jun 15; 136(12):943-5. PubMed ID: 10955155
    [No Abstract] [Full Text] [Related]

  • 18. Treatment of Crohn's disease at the turn of the century.
    Bickston SJ, Cominelli F.
    N Engl J Med; 1998 Aug 06; 339(6):401-2. PubMed ID: 9691110
    [No Abstract] [Full Text] [Related]

  • 19. The effectiveness of budesonide therapy for Crohn's disease.
    Kane SV, Schoenfeld P, Sandborn WJ, Tremaine W, Hofer T, Feagan BG.
    Aliment Pharmacol Ther; 2002 Aug 06; 16(8):1509-17. PubMed ID: 12182751
    [Abstract] [Full Text] [Related]

  • 20. [For treatment decision the age to be taken into account. In Crohn's disease and ulcerative colitis attention to be paid to the age at manifestation].
    MMW Fortschr Med; 2009 May 07; 151(19):38-9. PubMed ID: 19827443
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.